Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for BEAM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 7.523M
March 31, 2026 96.61M
December 31, 2025 1.886M
September 30, 2025 1.675M
June 30, 2025 1.109M
March 31, 2025 473.38M
December 31, 2024 3.444M
September 30, 2024 1.262M
June 30, 2024 0.133M
March 31, 2024 2.897M
December 31, 2023 33.71M
September 30, 2023 36.78M
June 30, 2023 107.54M
March 31, 2023 98.42M
December 31, 2022 32.01M
September 30, 2022 1.562M
Date Value
June 30, 2022 22.34M
March 31, 2022 55.68M
December 31, 2021 21.54M
September 30, 2021 320.89M
June 30, 2021 160.44M
March 31, 2021 253.27M
December 31, 2020 129.99M
September 30, 2020 0.094M
June 30, 2020 -0.779M
March 31, 2020 193.01M
December 31, 2019 0.699M
September 30, 2019 2.692M
June 30, 2019 -0.02M
March 31, 2019 37.91M
December 31, 2018 120.07M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Twist Bioscience Corp. 3.787M
Prime Medicine, Inc. 0.361M
Intellia Therapeutics, Inc. 196.12M
Sana Biotechnology, Inc. 93.58M
Revolution Medicines, Inc. 2.420B